NCT06988553CompletedPhase 1
A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus
A Phase Ib, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 23 Dec 2025
Brief summary (registry, in English)
The purpose of this study is to evaluate the safety, tolerability, and PK of AZD5004 compared with placebo in Chinese participants with overweight/obesity with or without T2DM.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (actual)
- First submitted
- 16 May 2025
- Start date
- 17 Jun 2025
- Primary completion date
- 28 Nov 2025
- Lead sponsor
- Eccogene
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT06988553
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 45
- From 17 Jun 2025 to the primary completion date, 28 Nov 2025
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of, or any existing condition that influence the participant's ability to participate or affect the interpretation of the results of the study.
- Significant hepatic disease.
- History of acute pancreatitis and chronic pancreatitis, gallstones.
- Uncontrolled thyroid disease.
Other
- Known clinically significant gastric emptying abnormality.
- Abnormal renal function.
Who the study is looking for
- Aged 18 to 74 years inclusive at the time of signing the informed consent.
- Stable self-reported body weight for 3 months prior to Screening.
- \- 27 kg/m2 ≤ BMI ≤ 35 kg/m2 and weigh at least 60 kg at Screening.
- Diagnosed with T2DM for at least 6 months prior to signing the informed consent.
- HbA1c value at Screening of ≥ 7.0% and ≤ 10.5%
- BMI of ≥ 24 kg/m2 at the Screening Visit.
Age in the registry: 18 years to 74 years · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| West China Hospital，Sichuan University Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
| The Fourth Affiliated Hospital of Harbin Medical University Coordinator of this site? Confirm its status | Ha’erbin | China | Unknown status |
| The Second People's Hospital of Hefei Coordinator of this site? Confirm its status | Hefei | China | Unknown status |
| Jinan Central Hospital Coordinator of this site? Confirm its status | Jinan | China | Unknown status |
| Shanghai Pudong New District People's Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| General Hospital of Tianjin Medical University Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.